Compare WOR & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WOR | IRON |
|---|---|---|
| Founded | 1955 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.3B |
| IPO Year | 1994 | 2020 |
| Metric | WOR | IRON |
|---|---|---|
| Price | $52.32 | $64.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | $59.67 | ★ $103.18 |
| AVG Volume (30 Days) | 226.3K | ★ 447.7K |
| Earning Date | 03-24-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.46% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.25 | N/A |
| Revenue | ★ $1,153,762,000.00 | N/A |
| Revenue This Year | $18.05 | N/A |
| Revenue Next Year | $5.29 | $283.52 |
| P/E Ratio | $41.66 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $43.35 | $30.82 |
| 52 Week High | $70.91 | $99.50 |
| Indicator | WOR | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 52.62 | 54.50 |
| Support Level | $51.36 | $57.79 |
| Resistance Level | $57.97 | $69.36 |
| Average True Range (ATR) | 2.01 | 2.71 |
| MACD | 0.61 | 1.02 |
| Stochastic Oscillator | 83.00 | 76.29 |
Worthington Enterprises Inc is a designer and manufacturer of products and services, including manufactured metal products. The company operates under two reportable operating segments: Consumer Products and Building Products. The consumer Products business has a diverse product offering in the tools, outdoor living and celebrations categories, including propane-filled cylinders for torches, handheld torches, specialized hand tools, drywall tools, accessories and gas grills, and others. And the Building Products business engaged in providing pressurized containment solutions, providing critical components in the residential, non-residential, and repair and remodel end markets through essential categories. The company derives majority of the revenue from Building Products segment.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.